Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program
18 nov. 2024 04h00 HE
|
Quell TX
Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress preclinical and clinical development of the selected...
Quell Therapeutics to Participate at Upcoming Healthcare Investor Conferences
06 nov. 2024 07h30 HE
|
Quell TX
London, UK – November 6, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,...
Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses
22 oct. 2024 07h00 HE
|
Quell TX
London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,...
Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
24 sept. 2024 05h30 HE
|
Quell TX
Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term relationship to provide Quell with additional...
Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors
10 juil. 2024 07h00 HE
|
Quell TX
Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in...
Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients
04 juin 2024 13h30 HE
|
Quell TX
Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...
Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
02 mai 2024 07h00 HE
|
Quell TX
Data demonstrating Quell’s ability to engineer Tregs to enhance their specific targeting and durability while maintaining their suppressive function and phenotypic stability to be presented in Oral...
Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
09 juin 2023 02h00 HE
|
Quell TX
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as...